Arrowhead Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Arrowhead Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials 3 currently recruiting 6 completed top decile by trial count

Arrowhead Pharmaceuticals: 15 sponsored US clinical trials, 3 recruiting.

Arrowhead Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 7 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Severe Hypertriglyceridemia, with 3 trials.

Top-decile sponsor footprint

Arrowhead Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

15 total, page 1 of 1

RECRUITING Phase 3

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771
RECRUITING Phase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770
RECRUITING Phase 3

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790
ACTIVE NOT RECRUITING Phase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016
ACTIVE NOT RECRUITING Phase 3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003
ACTIVE NOT RECRUITING Phase 3

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

NCT06347133
ACTIVE NOT RECRUITING Phase 2

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

NCT05217667
ACTIVE NOT RECRUITING Phase 3

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084
COMPLETED Phase 2

Study of ARO-APOC3 in Adults With Dyslipidemia

NCT05413135
COMPLETED Phase 2

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

NCT04998201
COMPLETED Phase 2

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
COMPLETED Phase 2

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT04720534
COMPLETED Phase 1

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT04169711
COMPLETED Phase 2

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
TERMINATED Phase 2

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 7

Therapeutic Areas

Severe Hypertriglyceridemia 3
Hypertriglyceridemia 2
Homozygous Familial Hypercholesterolemia 2
Mixed Dyslipidemia 1
Familial Chylomicronemia 1
Clear Cell Renal Cell Carcinoma 1
Dyslipidemias 1

What is open in the Arrowhead Pharmaceuticals pipeline

3 recruiting of 15 indexed (20% open); 6 completed (40%).

Phase mix: 7 late (III/IV) vs 8 early (I/II) (balanced across stages).

Top condition: Severe Hypertriglyceridemia (3 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Arrowhead Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 15 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

Arrowhead Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%20%40%60% Total trials Recruiting share Arrowhead PharmaceuticalsAllakosArbor Research Collaborative for HealthArena PharmaceuticalsAscentage Pharma GroupAcera SurgicalAlign TechnologyAltruBioAlvernia University
Arrowhead Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Arrowhead Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Arrowhead Pharmaceuticals page

15 registered trials is a research-attention snapshot, not an endorsement of Arrowhead Pharmaceuticals or any single study.

  • 3 of Arrowhead Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Severe Hypertriglyceridemia is the condition Arrowhead Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Severe Hypertriglyceridemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Arrowhead Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.